Solomon Moshkevich, who serves as President, Clinical Diagnostics at Natera, Inc. (NASDAQ: NTRA), executed a series of open-market sales totaling 4,639 shares of the company’s common stock on February 2nd and 3rd, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The aggregate proceeds from these trades amounted to $1,072,537. The share prices in the transactions ranged from $228.50 to $234.00. The disposition of stock was carried out pursuant to a Rule 10b5-1 trading plan.
Detailed disclosures in the filing show the following lot-level activity on February 2nd: 80 shares sold at $228.50; 878 shares sold at a weighted average price of $229.9577 (price range $229.5700 to $230.5150); 576 shares at a weighted average of $230.8399 (price range $230.6150 to $231.1400); 850 shares at a weighted average of $232.3253 (price range $231.94 to $232.92); 600 shares at a weighted average of $233.2367 (price range $232.94 to $233.82); and 16 shares at $234.00. On February 3rd, the filing shows an additional sale of 1,639 shares at $230.7680.
After these transactions, Moshkevich is reported to directly own 137,847 shares of Natera. Based on the most recent share price cited in the filing, $205.61, those holdings are currently valued at approximately $28.3 million.
Market performance for Natera has been volatile in recent periods. The stock has gained 46.7% over the past six months but declined 11.2% in the most recent week, according to the filing’s market context. Separate analysis from InvestingPro notes that Natera is trading above its Fair Value despite reporting robust revenue gains of 38.2%.
Beyond insider trading activity and valuation commentary, Natera continues to advance several clinical and regulatory efforts. The company has submitted a premarket approval application to the U.S. Food and Drug Administration for its Signatera CDx test, which is designed to detect molecular residual disease in bladder cancer patients. The submission follows results from a phase 3 clinical trial that indicated significant improvements in survival for patients tested with Signatera CDx.
In transplant diagnostics, Natera has completed enrollment for a trial of its Prospera Heart test, a noninvasive assay intended to monitor heart transplant recipients and potentially reduce reliance on invasive biopsies. That study includes more than 300 patients across 17 transplant centers in the United States.
The company is also preparing to present data from its EXPAND trial, which focuses on fetal genetic screening, at an upcoming medical meeting. In parallel, Natera has introduced a new artificial intelligence model intended to improve cancer recurrence risk assessment when used alongside its Signatera MRD test.
On the financial front, Canaccord Genuity has maintained a Buy rating on Natera. The firm cited strong preliminary fourth-quarter results, including expected revenue growth of nearly 40% year-over-year and an approximate 17% increase in test volume for the period.
Context and implications
The Form 4 filing confirms that the sale was executed under a prearranged trading plan rather than an ad-hoc disposition. The company’s simultaneous clinical and regulatory activity - from the Signatera CDx FDA submission to Prospera Heart enrollment completion and upcoming EXPAND data - underscores an active product development pipeline running alongside the reported strong revenue trajectory.
The filing does not indicate any new material corporate events beyond the disclosed trades and the ongoing clinical, regulatory and analyst developments cited above.